$5995 | Single User
$8995 | Global License

Medical Affairs Reputations (US): Multiple Sclerosis
[Lowest Price Guaranteed: $5,995]

Published by FirstWord Pharma: 01 Jul 2015 | 248 | In Stock
Related Topics: Aubagio (Teriflunomide) , Medical , Novartis , Products , Tecfidera (Dimethyl Fumarate) , Tysabri (Natalizumab)

Introduction

Introduction


Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition and where work is still needed.


As well as this timely report weighing up the performance of the European Medical Affairs teams, you can also get an equivalent report for Europe. If you buy both reports, we'll save you time and effort by giving you an additional free report that clearly sets out the differences in findings between both regions.


We asked neurologists who see patients with Multiple Sclerosis for their opinions on the Medical Affairs professionals they had dealt with in relation to at least one of the 9 MS drugs considered. Their frank responses reveal key areas of concern for you and what you should focus on to improve neurologists’ satisfaction. Areas where the teams are giving a solid performance are also highlighted.


Puchase Reasons


Get Answers to Key Questions


  • What are the critical issues that physicians want help with from European Medical Affairs (MA) teams on?

  • How satisfied are physicians with the overall performance of MA teams? And how can performance be improved?

  • Which aspects of the services MA teams are providing are failing to satisfy physicians’ needs?

  • What are the preferred ways in which physicians want to interact with MA experts?

  • Which MA teams do physicians rate the best or worst for the products surveyed?

  • Products Included in Report


  • Bayer

  • Betaseron (Interferon-beta-1b)

  • Biogen

  • Avonex (Interferon-beta-1a)

  • Tecfidera (Dimethyl Fumarate)

  • Tysabri (Natalizumab)

  • Merck Serono

  • Rebif (Interferon-beta-1a)/BulletPoint>

  • Novartis

  • Extavia (Interferon-beta-1b)

  • Gilenya (Fingolimod)

  • Sanofi

  • Aubagio (Teriflunomide)

  • Teva

  • Copaxone (Glatiramer acetate)

  • Key Issues Explored


  • How physicians use the services of Medical Affairs teams

  • The importance of responding promptly to medical inquiries

  • The need-gap analysis of Medical Affairs roles – collectively and by product

  • The importance to physicians of regular, accurate, unbiased scientific and product information

  • Which Medical Affairs teams are performing best and worst for the Multiple Sclerosis sector

  • Methodology


    Sample Distribution -

    100 neurologists across the US


    Interviewing Methodology

    Data was collected via a 15-minute internet-based questionnaire that were carefully analysed.


    Screening Criteria


    Respondents screened to ensure that they:


  • See at least 10 patients for Multiple Sclerosis in a typical month

  • Have been in active practice for between 3 and 35 years

  • Devote at least 50% of time to direct patient care

  • Have had an interaction with a Medical Affairs professional in the past 6 months for at least one of the listed products

  • About FirstWord Reports


    FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence


  • FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

  • FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
  • Table of Contents
    for Medical Affairs Reputations (US): Multiple Sclerosis

    • 1.Research aims and objectives

      2.Executive summary

      3.Current status of interactions with different Medical Affairs teams

      4.Competitive evaluation of Medical Affairs teams’ performance on various attributes

      5.Preferred interaction media, frequency, and suggestions for improvement

      6.Appendix

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    248 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Building Strong Cross-Functional Medical Affairs Teams
    IntroductionCould your Medical Affairs team be better integrated for more effective cross-functional...
    01 May 2015 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputation (EU5): Biosimilar mAbs in Inflammatory Disorders
    IntroductionBased on survey results from 150 rheumatologists, dermatologists, and gastroenterologist...
    01 Feb 2015 by FirstWord Pharma USD $5,995 More Info
    Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    08 Dec 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology (EU5): Oncologists Rate Key Products and Companies
    IntroductionAs the cancer drug market continues to face significant challenges in an environment of ...
    02 Dec 2014 by FirstWord Pharma USD $3,900 More Info
    Reshaping Medical Affairs: delivering value to KOLs and payers
    IntroductionHistorically, the key role of Medical Affairs was supporting the initial regulatory appr...
    21 Aug 2014 by FirstWord Pharma USD $695 More Info
    Medical Affairs Reputations in Oncology: Oncologists Rate Key Products and Companies
    IntroductionAs the oncology drug market continues to face significant road bumps in terms of develop...
    14 Aug 2014 by FirstWord Pharma USD $3,900 More Info
    Physician Views: How do pulmonologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    09 Jul 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    18 Jun 2014 by FirstWord Pharma USD $695 More Info
    Physician Views: How do oncologists value medical affairs teams – what could they be doing better?
    Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
    22 May 2014 by FirstWord Pharma USD $695 More Info
    Ensuring Optimal Medical Affairs Performance: Delivering Measurable Value
    IntroductionIn this era of transparency, Medical Affairs is rapidly becoming the new voice of Pharma...
    01 May 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Medical Affairs Reputations (US): Multiple Sclerosis | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...